KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Short-term Investments: 2012-2024

Historic Short-term Investments for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Dec 2024 value amounting to $384.3 million.

  • Supernus Pharmaceuticals' Short-term Investments fell 65.07% to $129.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.8 million, marking a year-over-year decrease of 65.07%. This contributed to the annual value of $384.3 million for FY2024, which is 113.70% up from last year.
  • As of FY2024, Supernus Pharmaceuticals' Short-term Investments stood at $384.3 million, which was up 113.70% from $179.8 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Short-term Investments ranged from a high of $384.3 million in FY2024 and a low of $133.9 million during FY2020.
  • For the 3-year period, Supernus Pharmaceuticals' Short-term Investments averaged around $310.8 million, with its median value being $368.2 million (2022).
  • In the last 5 years, Supernus Pharmaceuticals' Short-term Investments surged by 170.26% in 2022 and then plummeted by 51.16% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Short-term Investments (Yearly) stood at $133.9 million in 2020, then rose by 1.76% to $136.2 million in 2021, then skyrocketed by 170.26% to $368.2 million in 2022, then plummeted by 51.16% to $179.8 million in 2023, then soared by 113.70% to $384.3 million in 2024.